Axxcess Wealth Management 13F: Cuts LLY Stake by $14M

Axxcess Wealth Management lowered its stake in Eli Lilly and Company (NYSE:LLY) by 56.3% during the third quarter, according to a Form 13F filing with the Securities and Exchange Commission on October 21, 2026. Eli Lilly shares closed at $1,270.75 on the day of the filing.

LLY Eli Lilly and Company

$1,272.20 ▲ +18.33% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Axxcess Wealth Management's Eli Lilly Position

The firm sold 12,282 shares of the pharmaceutical company during the quarter. That left it holding 9,539 shares. The remaining stake had a value of $11,038,261 at the end of the period, down from its previous holding of 21,821 shares.

Other Institutional Activity in Eli Lilly

PensionDanmark Pensionsforsikringsaktieselskab trimmed its holdings by 3,570 shares, ending with 145,819 shares worth $168,724,249. James Hambro & Partners grew its holdings by 507 shares, ending with 1,831 shares worth $2,123,428. Annex Advisory Services grew its holdings by 29,346 shares, ending with 33,181 shares worth $38,393,602. Focus Financial Network grew its holdings by 632 shares, ending with 7,646 shares worth $8,847,034. B. Riley Wealth Advisors grew its holdings by 2,742 shares, ending with 25,044 shares worth $28,977,792.

Eli Lilly and Company Stock Up 1.4%

Eli Lilly recently traded around $1,301.24 as of October 22, 2026, putting it up about 2.4% since the filing. The stock sits near its 52-week high of $1,311.75.

Recent Earnings

Eli Lilly generated $79.67 billion in trailing-twelve-month revenue with earnings of $29.79 per share. The company posts its next financial results on October 29, 2026.

Dividend

Eli Lilly pays an annual dividend rate of $6.92 per share, yielding 0.54% with a payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Company insiders executed several transactions prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at a price of $1,190.00 for a total value of $5,950,000. Officer Donald A. Zakrowski sold 2,000 shares on August 10, 2026, at a price of $1,185.01 for a total value of $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at a price of $1,175.10 for a total value of $7,638,150.

Analysts Set New Price Targets

JP Morgan maintained an Overweight rating with a target of $1,500.00 on September 28, 2026. Morgan Stanley maintained an Overweight rating, lifting its target from $1,419.00 to $1,430.00 on October 7, 2026. Cantor Fitzgerald maintained an Overweight rating, raising its target from $1,410.00 to $1,440.00 on October 8, 2026. RBC Capital reiterated an Outperform rating with a target of $1,500.00 on October 12, 2026. Leerink Partners maintained an Outperform rating and raised its target from $1,309.00 to $1,316.00 on October 21, 2026. The stock carries a consensus buy rating from 30 analysts.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Headquartered in Indianapolis, Indiana, the company focuses on treatments for diabetes, oncology, immunology, and neuroscience.

Bottom Line

Investors will look toward Eli Lilly's upcoming earnings report on October 29, 2026, for further updates on drug sales and product demand. Future institutional filings will show whether other funds follow Axxcess Wealth Management in trimming their positions.